KDM1A and small cell lung carcinoma: GlaxoSmithKline reported also a selective LSD1 inhibitor, GSK2879552 (Fig. 4), which entered a phase I study in AML (ClinicalTrials.gov identifier: NCT02177812) and in small cell lung cancer (SCLC) (ClinicalTrials.gov identifier: NCT02034123).